Biovail Narrows Revenue Guidance; Projected Earnings Remains Unchanged
This article was originally published in The Pink Sheet Daily
Executive Summary
The company revises its revenue guidance to $820-$920 mil. from $800-$940 mil. Estimate reflects stronger than expected Wellbutrin XL growth as well as lagging Cardizem LA, Teveten and Zovirax sales.
You may also be interested in...
Biovail CEO Joins From MDS Pharma
Biovail CEO John Squires, PhD, is joining the company after six years at MDS Pharma
Biovail CEO Joins From MDS Pharma
Biovail CEO John Squires, PhD, is joining the company after six years at MDS Pharma
Biovail To Complete Sales Force Reorganization In April; Adds Specialty Reps
Increased SG&A expenses associated with the sales force reorganization caused Biovail to miss its 2003 financial guidance. The company expects to out-license tramadol and once-daily metformin.